REMINDER: Registrations to apply for the 100% Fund grant in infant leukemia due Feb 1

C17 is pleased to announce a call for applications for the The 100% Fund Grant Competition targeting INFANT LEUKEMIA.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing infant leukemia will be considered for the 2019 100% Fund Grant Competition.

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates. 

Please note that this is a reissue of the call for application for research in infant leukemia. The 100% Fund LOI for infant leukemia is now replaced by a Letter of Registration (LOR) that is due by 1 Feb 2019 (4pm MT).  The registration form can be downloaded from C17.ca and asks for brief administrative details, draft project title, research areas and a very brief/general project description. The 100% Fund Grants targeting infant leukemia will be reviewed in conjunction with the ongoing 2018/2019 Round 22 of grants due 13 April 2019.

The submission deadline for C17 LORs is February 01, 2019 at 4 PM MT.

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

Advertisements

Toolbox for International Childhood Cancer Day – celebrated worldwide on February 15

Toolbox: https://www.dropbox.com/sh/b5gderkv40fc8mf/AADScr36d6m-OCjX-_L6xXM4a?dl=0

This year, ICCD is focusing on reducing cancer and treatment related pain. In 2011, a study found that 65.6% of countries worldwide offered no palliative care services for children. Help us fight for #NoMorePain.

What is ICCD? International Childhood Cancer Day is a global collaborative campaign to raise awareness and promote an increased appreciation and deeper understanding of the challenges faced by children and adolescents with cancer, the survivors and their families. ICCD spotlights the need for more equitable access to treatment and care for all children with cancer, everywhere.

DOWNLOAD: Please feel free to download the ICCD 2019 Toolkit HERE. You can find the artwork for the new ICCD logo, as well as custom posters, graphs and social media tools, specifically created for member organizations to use in the event planning process to raise awareness about the need to eliminate pain and suffering of children with cancer.

EDUCATE: The CCI Board of Trustees applaud the 2018 release of the WHO’s palliative care guide entitled, Integrating Palliative Care and Symptom Relief into Paediatrics: A WHO guide for healthcare planners, implementers and managers. CCI encourages all members to share this valuable document with those in your countries who provide the planning, implementing, managing or assuring access to quality of palliative care for children. Download HERE.

ADD FRAME TO SOCIAL MEDIA: Raise awareness about the need to reduce cancer and treatment related pain by participating in our #NoMorePain Campaign! Use our Facebook Frames found in the Toolkit to raise awareness of children and their families in your country. Please use the hashtag #NoMorePain as well as #ICCD2019 when posting on social media.

Recording of LLSC WEBCAST now available – Children & Teens with Cancer: Challenges at School after Treatment


Speaker: Ann Klinck, M.A.Sc., C. Psych. Assoc., School Liaison, Pediatric Cancer School Support Program, Children’s Hospital, London Health Sciences Centre, Ontario

This training is useful for those who support children and teens during and after the cancer experience including parents, relatives, teachers, school support staff and nurses. The recording of this webcast can found on our Website at: www.llscanada.org/events/children-teens-with-cancer-challenges-at-school-after-treatment?src1=22346&src2=

Questions? Contact Fred Ho at The Leukemia & Lymphoma Society of Canada | fred.ho@lls.org | http://www.llscanada.org

Would you like $1000 in travel funds? C17 Norma Auger applications due Feb 1

Download the application form at C17.ca under committees>education: www.c17.ca/index.php?cID=67


The goal of the C17 Norma Auger Education Fund is to support health professionals involved in pediatric Oncology/Hematology/BMT across Canada advance their knowledge, skills and experience and to promote presentations and knowledge translation by these health professionals. This is an annual scholarship offered by the C17 Education Committee with funding from the Childhood Cancer Canada Foundation.

Eligibility:   Non-MD Pediatric Oncology/Hematology/BMT health care professionals working in Canada.

Application deadlines: May 1st, August 1st, November 1st, February 1st annually

Individuals applying must be involved in a C17 Oncology, Hematology or BMT program and is not a physician resident or university student (can be nursing, CRA, social work, child life, physiotherapy, occupational therapy, etc).

A maximum of $1000.00 Canadian will be awarded to each applicant.

Applicants can re-apply for funding each year but priority will be given to those who have not received funding previously. This grant is not retroactive.

Register for the N2 AGM by Jan 22.

REMINDER: Please register online no later than Tuesday January 22, 2019.

One of the benefits of membership in N2, either through C17 or your local institutional or provincial membership, is that you can attend the annual meeting of members. This meeting has an educational and information focus, providing updates and presentations on current issues impacting clinical trials in Canada, as well as updates from the various N2 committees.

You are cordially invited to attend the 12th Annual N2 Meeting to be held at Vantage Venues (previously the St. Andrew’s Club and Conference Centre) http://www.vantagevenues.com in downtown Toronto on February 5-6, 2019. (Please note this is a Tuesday and Wednesday).

The full agenda can be found HERE.

As a member of N2, you are encouraged to attend this important meeting and network with your colleagues. The N2 Annual Meeting is also open to additional members of your clinical research organization. If they wish to accompany you to the meeting, they are welcome to attend.

To view information about the event and register, please follow this link: https://n2canada.ca/n2-annual-meeting/

Attendees requiring travel assistance must contact Karen Arts karen.arts@n2canada.ca for pre-approval. Assistance of a maximum of $750 is available for one member per organization, outside the greater Toronto area for the cost of travel to and from Toronto. The funds may be used for flight and/or rail costs only.

For anyone in your clinical research organization wishing to attend, please ensure they register by completing the on-line registration here: https://secure.e-RegisterNow.com/cgi-bin/mkpayment.cgi?state=2772

Due to increasing economic pressures, the N2 Board of Directors has approved a registration fee of $50.00 (+HST) per person. This fee of $50 plus HST is payable by credit card only. This fee is to offset some charges incurred on catering, venue rental and AV equipment required to hold the two-day annual meeting. To ensure accurate catering estimates it is imperative we know the total number of attendees ahead of time by having everyone register. Please register online no later than Tuesday January 22, 2019.

We hope to see you at the meeting.

Shelley

100% Fund Grant Competition — reissue of call for grants targeting INFANT LEUKEMIA [registration due 01-Feb-2019]

C17 is pleased to announce a call for applications for the The 100% Fund Grant Competition targeting INFANT LEUKEMIA.

The purpose of The 100% Fund Grant Competition is to target directly pediatric cancers that are rare and hard to treat—cancers that have not responded to available therapies. Applications addressing infant leukemia will be considered for the 2019 100% Fund Grant Competition.

Projects can range from discovery to clinical trials, but must be focused towards a treatment intervention. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

Please note that this is a reissue of the call for application for research in infant leukemia. The 100% Fund LOI for infant leukemia is now replaced by a Letter of Registration (LOR) that is due by 1 Feb 2019 (4pm MT).  The registration form can be downloaded from C17.ca and asks for brief administrative details, draft project title, research areas and a very brief/general project description. The 100% Fund Grants targeting infant leukemia will be reviewed in conjunction with the ongoing 2018/2019 Round 22 of grants due 13 April 2019.

The submission deadline for C17 LORs is February 01, 2019 at 4 PM MT.

Application forms and the guidance document also can be downloaded from the C17 website (www.c17.ca) under Committees> Research Network.

New Investigator Cancer Trials Practicum 2019 – 2020 [applications due 11-Feb-2019]

The Canadian Cancer Trials Group (CCTG) is very excited to announce that the the 2019-2020 New Investigator Cancer Trials Practicum applications are open. This is a unique opportunity for new investigators to access hands on training and practical work in the field of cancer clinical trials. The purpose of the CCTG New-Investigator Cancer Trials Practicum is to deliver a training program that includes practical trial experience at cancer sites across the country over a one-year period. This opportunity is the first of its kind in Canada enabling the best and brightest new oncology researchers to acquire training and experience.
New Investigator Cancer Trials Practicum 2019 - 2020

Application deadline is February 11, 2019

To find out more: New Investigator Cancer Trials Practicum

ADOLESCENT & YOUNG ADULT SURVIVORSHIP SYMPOSIUM: A NEW VISION (March 20-21, 2019 in Toronto)

https://uhnevents.regfox.com/aya-survivorship-symposium

The Adolescent and Young Adult Survivorship Symposium: A New Vision aims to engage local, national and international experts and trainees to build a framework for the delivery of survivorship care for survivors of young adult cancer.

Keynote Speaker:

Dr. Lois Travis, MD, ScD
Director of the Cancer Survivorship Research Program
Melvin and Bren Simon Cancer Centre, Indiana University

Day 1: How Can a Program Can Help Young Adults with Cancer?

Learn about and develop skills in identifying, assessing and intervening on the unique needs of young adults with cancer. Participants will gain an understanding of effective models of care for addressing AYA-specific issues.

Day 2: Surveillance and Screening for Survivors of Adolescent and Young Adult Cancer

Participants will have increased awareness and knowledge of common treatment-related late effects in younger adult cancer survivors and evidence-based interventions for managing them.

See link for registration, agenda, location, contact information and accommodation details.  https://uhnevents.regfox.com/aya-survivorship-symposium

In memory of Dr. Melvin Freedman

Dr. Melvin (Mel) Freedman, former Head of the Division of Haematology/Oncology at SickKids, passed away on January 2. He leaves a rich legacy from which his colleagues in Haematology/Oncology continue to benefit. Below, a tribute from the team:

Dr. Melvin Freedman, an iconic international leader in the field of paediatric haematology/oncology since the late 1960s, passed away in his sleep on January 2, 2019 after a long and courageous battle with cancer.

Mel was born and raised in New Brunswick, completed his medical training at McGill University, and his paediatric and haematology residencies in the United States before being recruited to SickKids in 1971, where he spent his entire professional career. Over the years, many institutions from around the world attempted to recruit Mel, but he was passionate about SickKids and never saw the need to move elsewhere.

Mel’s career spanned a remarkable revolution in childhood cancer care. He witnessed the initial uses of chemotherapy to treat a variety of childhood cancers and cared for many of the first children with leukemia who were actually long-term survivors of their disease. Toward the close of his career, he saw the emergence of molecular and genomic technologies being applied to the practice of paediatric oncology and haematology.

In addition to being a compassionate, caring and dedicated doctor to his young patients and their parents, Mel was a brilliant, productive scientist whose work expanded our understanding of haematopoiesis, leukemia stem cell biology, development of rational approaches to leukemia clinical trial design and innovative management of haemoglobinopathies, including allogeneic stem cell transplantation. Mel also pioneered research and treatment of congenital neutropenia and other inherited bone marrow failure syndromes.

Mel’s legacy is measured not only in the thousands of children who benefited from his care and research, but also the innumerable students, residents, junior faculty, nurses and all allied health-care colleagues who he mentored with wisdom, kindness and patience – who went on to build their own careers around the world. Mel was an inspiring teacher, who showed his students the value of asking cutting questions and had the gift of real wit that could level any pretense.

Among the many accolades recognizing his many contributions, one that resonates particularly is the Medical Staff Association Citizenship Award in 2012 — a testament to a truly renaissance man who selflessly gave so much to his colleagues, his patients and our institution.

He was a greatly admired leader both here and at the University of Toronto in many capacities, including Head of the Division of Hematology/Oncology in the 1990s, Chair of the SickKids Research Ethics Board and Head of the Department of Pediatrics Academic Promotions Committee. In each of these roles, he was respected at all levels of governance and admired by all who came to know him. Even since his retirement and during his illness, Mel continued to enjoy hearing stories about and taking great pride in the successes of his colleagues and friends.

Mel leaves behind his wife Lila, his children Monica and Jamie, and many grandchildren. His passing leaves a great hole in the hearts of all who knew him in their academic or personal lives. At the same time, we know that our lives are much the richer for having had the honour to have been in his company.

Oh, Canada! Proceedings from DIA Canada 2018

Let your fingers do the walking this morning: Venture to Ottawa, Ontario, and read expert reports from our recent DIA Annual Canadian Meeting 2018 in your new Global Forum.

Last Call: Please take this five-minute Global Forum Readers’ Survey to tell us how we’ve done since our new re-design and a $100 gift card may be yours!

EXPLORE DIA CANADA 2018
Thank you for your loyal readership!